A pilot study led by Ai-Ling Lin at the University of Missouri found that a low daily dose of rapamycin, a drug already used to prevent organ transplant rejection, improved blood flow to the brain in healthy adults aged 45 to 65 who carry the APOE4 gene variant. The effect was not seen in participants without the variant. The study was published in the Journal of Cerebral Blood Flow & Metabolism.
APOE4 is linked to a substantially higher risk of Alzheimer's disease later in life, and Lin's team has been looking at changes in the brain that occur before memory problems appear. Reduced blood flow in certain brain regions can show up years before noticeable memory difficulties in people who carry APOE4, which is why researchers see these circulation changes as a possible early warning sign.
The work grew out of Lin's earlier experiments in mice carrying APOE4, in which rapamycin slowed brain aging and increased blood flow. The new study asked whether similar effects would appear in people who are genetically predisposed to Alzheimer's but have not developed it. All participants took the drug for four weeks, and the improvement in circulation was limited to the APOE4 carriers.
The researchers noted that women carrying APOE4 showed the largest gains in brain blood flow, a finding that stands out given that nearly two-thirds of people living with Alzheimer's are women. Lin framed the work as an example of precision medicine, meaning an effort to identify which people are most likely to benefit from a particular treatment rather than assuming a drug will work equally well for everyone.
The study was not designed to determine whether rapamycin prevents Alzheimer's or preserves memory over time, and the authors say more research is needed to learn whether the blood flow changes lead to lasting benefits for brain health.